MX2024003333A - Terapia de triple agente para el tratamiento de cáncer. - Google Patents

Terapia de triple agente para el tratamiento de cáncer.

Info

Publication number
MX2024003333A
MX2024003333A MX2024003333A MX2024003333A MX2024003333A MX 2024003333 A MX2024003333 A MX 2024003333A MX 2024003333 A MX2024003333 A MX 2024003333A MX 2024003333 A MX2024003333 A MX 2024003333A MX 2024003333 A MX2024003333 A MX 2024003333A
Authority
MX
Mexico
Prior art keywords
cancer
treatment
treatment regimen
cancer treatment
metronomic
Prior art date
Application number
MX2024003333A
Other languages
English (en)
Spanish (es)
Inventor
Larry Weisenthal
William Grace
Original Assignee
Cytometric Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytometric Therapeutics Inc filed Critical Cytometric Therapeutics Inc
Publication of MX2024003333A publication Critical patent/MX2024003333A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2024003333A 2021-09-15 2022-09-15 Terapia de triple agente para el tratamiento de cáncer. MX2024003333A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163244412P 2021-09-15 2021-09-15
PCT/US2022/043601 WO2023043883A1 (en) 2021-09-15 2022-09-15 Triple-agent therapy for cancer treatment

Publications (1)

Publication Number Publication Date
MX2024003333A true MX2024003333A (es) 2024-05-20

Family

ID=85603487

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024003333A MX2024003333A (es) 2021-09-15 2022-09-15 Terapia de triple agente para el tratamiento de cáncer.

Country Status (10)

Country Link
US (1) US12611411B2 (cg-RX-API-DMAC7.html)
EP (1) EP4401720A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024531765A (cg-RX-API-DMAC7.html)
KR (1) KR20240060625A (cg-RX-API-DMAC7.html)
CN (1) CN118159262A (cg-RX-API-DMAC7.html)
AU (1) AU2022345084A1 (cg-RX-API-DMAC7.html)
CA (1) CA3231639A1 (cg-RX-API-DMAC7.html)
IL (1) IL311229A (cg-RX-API-DMAC7.html)
MX (1) MX2024003333A (cg-RX-API-DMAC7.html)
WO (1) WO2023043883A1 (cg-RX-API-DMAC7.html)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ587706A (en) 2008-03-18 2012-12-21 Genentech Inc Combinations of an anti-her2 antibody-drug conjugate and chemotherapeutic agents, and methods of use
US20100189683A1 (en) 2008-11-14 2010-07-29 Ascenta Therapeutics, Inc. Pulsatile Dosing of Gossypol for Treatment of Disease
AU2014324729B2 (en) * 2013-09-26 2019-08-22 Five3 Genomics, Llc Systems, methods, and compositions for viral-associated tumors

Also Published As

Publication number Publication date
KR20240060625A (ko) 2024-05-08
CN118159262A (zh) 2024-06-07
WO2023043883A1 (en) 2023-03-23
US12611411B2 (en) 2026-04-28
US20250127791A1 (en) 2025-04-24
IL311229A (en) 2024-05-01
EP4401720A4 (en) 2025-07-30
AU2022345084A1 (en) 2024-03-28
CA3231639A1 (en) 2023-03-23
JP2024531765A (ja) 2024-08-29
EP4401720A1 (en) 2024-07-24

Similar Documents

Publication Publication Date Title
MX2018003698A (es) Terapia adjuntiva con 25-hidroxi vitamina d y articulos de los mismos.
CL2018000706A1 (es) Derivados de pirazolopirimidina como inhibidores btk para el tratamiento del cancer.
CO2019001537A2 (es) Sistema y método para terapia médica controlada
CR20170085A (es) Terapia adjuntiva con 25-hidroxi vitamina d
AR107871A1 (es) Combinaciones de inhibidores de lsd1 para su uso en el tratamiento de tumores sólidos
BR112017006113A8 (pt) usos de auristatina, composições farmacêuticas, formas de dosagem para o tratamento de câncer e kits.
MX391719B (es) Agentes de quimioembolizacion.
MX2018016332A (es) Quimioterapias de combinacion.
CL2023000289A1 (es) Combinaciones para el tratamiento de cáncer
BR112018013896A2 (pt) formulações para o tratamento do câncer de bexiga
ECSP21031200A (es) Uso de reboxetina para el tratamiento de narcolepsia
MX2019003134A (es) Terapia de combinacion.
MX2022014792A (es) Cocristales, composiciones farmaceuticas de los mismos y metodos de tratamiento que los implican.
MX377118B (es) C. novyi para el tratamiento de tumores solidos en humanos.
CL2024002763A1 (es) Dosificación no lineal de mirdametinib
MX2024003918A (es) Agente terapeutico que induce citotoxicidad para usarse en terapia del cancer.
MX2018013873A (es) Irinotecan nanoliposomico para usarse en el tratamiento del cancer de pulmon de celulas pequeñas.
CL2025001129A1 (es) Anticuerpo anti-ttr; y su uso para tratar amiloidosis de transtiretina.
MX2017015532A (es) Terapia de combinacion pac-1.
MX2022006500A (es) Terapia de combinacion que involucra compuestos macrociclicos de diarilo.
MX2024012392A (es) Terapia combinada para el tratamiento del cancer
PY1944026A (es) Ácido ascórbico y compuestos quinona en combinación con un agente antiparasitario para tratar enfermedades parasitarias
BR112021017957A2 (pt) Derivado tienoeterocíclico, método de preparação do mesmo e uso médico do mesmo
MX2021014523A (es) Metodos para tratar colangiocarcinoma.
MX2018012392A (es) Terapias de combinacion para el tratamiento de cancer que comprenden un derivado de bacterioclorofila.